الفهرس 
Title: A pharmaceutical study on a drug for treatment of a certain ocular disorder
List of contentsOnly 14 pages are availabe for public view
 |  | from | 223 |  |  |
| | | from | 223 | | |
Abstract
Novel sustained release topical drug delivery systems are more preferable than conventional topical dosage forms for ocular administration as they enable dose reduction, patient compliance and avoid the drug loss associated with liquid eye drops.Glaucoma is one of the most serious ocular diseases as it is characterized by increased IOP and optical nerve damage that can lead to blindness, so that it must be under controlled treatment to avoid its complications. Carbonic anhydrase inhibitors are drugs used in treatment of glaucoma by inhibiting the aqueous fluid production resulting in reduction of the elevated IOP. Dorzolamide-HCl is a member of this class of medicaments with potent IOP lowering effect but it should be administered three times daily also its market product Trusopt® causes stinging effect on the eye due to its relatively low pH. Formulation of sustained release formulae for topical administration of Dorzolamide-HCl to be used once daily will avoid the frequent dosing, stinging effect and patient incompliance. Accordingly, our study aims to formulate Dorzolamide-HCl as sustained release formulae and our goal was achieved through this thesis as follows: Chapter I: Formulation and in-vitro evaluation of Dorzolamide-HCl proniosomal gel fotmulae Chapter II: Formulation and in-vitro evaluation of lyophilized Dorzolamide-HCl mini-tablets Chapter III: In-vivo pharmacodynamic evaluation of the selected formulae of Dorzolamide-HCl